Mint Labs

MainImage

151,162.50€

Out of 150,000.00€

investors

35

Est. ROI

810%

days left

--

Google Maps for the Brain

Finish date: 15/12/2015 Barcelona / Boston

Premoney valuation

5,596,812.00€

Percentage offered

2.68%

Est. ROI

810%

Exit horizon

2019

The project

Nearly 33% of the EU and US population are affected by brain diseases. Currently patients are diagnosed only after clinical presentation of the symptoms, when the disease has taken its course and destroyed significant portion of the brain.

There are currently more than 600 brain diseases, and most of them are still incurable. 

Significant time and resources are allocated to research and development of many new therapies for brain diseases. Drug discovery and development, from an initial disease treatment concept to a new drug application, is a complex, lengthy and expensive process. The timeline from initial concept to New Drug Application can range from 12 to 15 years. The cost of developing a new drug has been rising, with a current estimate of €2.35 billion ($2.6 billion), including the cost of failures. The high percentage of drug testing failures causes pharmaceutical companies to lose more than €72 billion ($80 billion) per year. 

Many drugs tested in the past failed to show efficacy and the currently approved treatments for the disease only treat symptoms and do not cure the underlying problem.  

In addition, another major problem in the design of clinical trials is the lack of accurate patient profiling -­ even very promising drugs with positive effects in animal studies fail in human trials. We most recently saw the Alzheimer’s disease Phase 3 trial failures of Alzheimer 3 APS and Flurizan MPC-­‐7869. The Flurizan trial cost was estimated at $150 million.

The pharmaceutical companies are faced with two great difficulties when evaluating new treatments:

  1. "What patients will respond to the drug?" - Is the compound is given to the correct subjects?
  2. "Is the drug working?" - Are the favorable effects of the compound detected?

 

The main subjacent problems are:

  1. The subjective evaluation of the symptoms of the disease, based on measures of cognitive performance and/or observations by the evaluator; and
  2. The inadequate selection of patients for the trials.
Screening, diagnosing and quantifying a disease like Alzheimer's involves methods that are either subjective, or depend on the mood and disposition of the patient. Basing a multi-million drug development on qualitative tests like this makes the process incredibly expensive and inefficient. The possibility of finding an effective cure for these diseases remains very small.

 

Mint Labs' solution

New in vivo imaging technology as Magnetic Resonance Imaging, provides a unique look inside the brain, without any harm to the patients. The issue however is that these images are complex, often with poor quality, and rely heavily on advanced software systems that require experts to run them. We can see the brain, well protected by the skull, and some of its details, but we are lacking fine information of the precise state of the brain tissue.

MRI brain slices

MRI acquires lots of information. You can think of MRI as cameras that takes hundreds of photos of the brain in black and white. But until now specialists still just look at one of these black and white 2d images, and still have a subjective and qualitative opinion about them.

We use the diffusion MRI image sequencing that allows reconstructing the brain connectivity and quantification of white matter tissue properties. In combination with other conventional MRI imaging techniques it lets us to capture and measure microstructural properties of the brain tissue and provide, non invasively, a uniquely detailed 3D neural map of the brain, allowing quantitative measuring, better categorization of patients and efficacy measuring, and cost-effective data management.

Thanks to our technology, development of brain drugs can rely upon hard data instead of subjective appreciations, radically decreasing the length and cost of the process.

 

Our product, CloudN, is a unique cloud-based 3D imaging data analysis and quantification without the need for any investment in data processing, storage hardware, or software. The platform is able to receive medical images acquired in preclinical and clinical trials from Pharmaceutical companies and/or specialists, hospitals and imaging centers. These images are then processed by the state‐of‐the‐art  algorithms developed  in  Mint Labs that are automatically employed in order to identify patterns and anomalies related to clinical outcomes. CloudN allows for non‐subjective in vivo quantification of brain structure and circuits, reduced time and costs in R&D, and accelerated development of new therapies for neurological diseases.

 

Mint Labs innovative work on neuroimaging analysis and visualization has been depicted in several occasions, for instance at CODE_n initiative exhibiting at the international CeBIT conference, in Hannover, Germany in 2014. Our Brain Connectome visualization was used by architecture designers Kram and Weisshaar with an incredible terapixel visualization of a 43 x 11m in the hall walls.

 

Use Cases: Multiple Sclerosis

Magnetic resonance imaging (MRI) of the brain is useful in the diagnosis and treatment of multiple sclerosis (MS), an inflammatory, demyelinating condition of the central nervous system (CNS) that is generally considered to be autoimmune in nature. Neurological impairment of MS patients is poorly associated with the lesion load observed on conventional MRI scans, partly due to the low sensitivity of conventional MRI in detection of grey-matter and white-matter damage. In order to overcome these limitations new MRI techniques have been developed.

See here Dr. Pablo Villoslada view on this disease, and how our technology can help accelerate the treatment for Multiple Sclerosis.

Business opportunity

THE MARKET

 

Globally, around 36 million people have Alzheimer's and other dementias, 6 million people have Parkinson and 2.5 million have multiple sclerosis. With increased life expectancy and aging population, these numbers are expected to double by 2030.

Additionally, the development of new medical treatment is extremely expensive. Clinical trials from testing on animal models (mouse, rats) to testing on a large group of patients can amount up to 70% of the total drug development cost – about €1.1 billion per drug ($1.2 billion). Patient recruitment represents by average 21% of the clinical trials expenditure, that is €23.7 million ($25.6 million). The difficulty of diagnosing patients at an early stage and the associated costs of patient recruitment for new treatment development create an insurmountable barrier with existing solutions.

► The availability of a quantitative measurement tool would make these clinical trials much cheaper, faster and more reliable.

 

Mint Labs can already operate as a pre-clinical services provider. That market is €730 million; but the greatest value of our platform will be for phases 2 and 3 of clinical trials since their goal is to evaluate the efficacy in groups of patients receiving the treatment or a placebo. Our quantification provides an objective way to evaluate this efficacy. After Q4 2015 we will start moving into the clinical trial market, which only for Alzheimer's, Parkinson's and Multiple Sclerosis is over €4,000 million

 

On the whole, we are targeting a global market close to €55 billion.

 


 

UNFAIR ADVANTAGE AND TECHNOLOGY TRACTION

The founders both hold PhD degrees in medical image analysis and visualization, specifically applied to neuroimaging – fundamental building blocks of the developed products. They developed a visualization and image processing software for the virtual dissection of white matter structures of the brain. Mint Labs' cloud-based system employs proprietary software tools to integrate thousands of images and data from a patient and creates a specific detailed 3D map of the brain. The complex algorithms are hosted in the cloud, powered by our partner Google. We use Leap Motion as an intuitive form of interaction with this 3D maps. This gives the advantage of allowing the doctor to interact and visualize patient images right at point of care, at the operating room. We use Unity3D to put together visualization and the interaction device.

Our platform supports the R&D work of several projects with top scientists and institutions in Barcelona:

  1. Hospital Clinic and Hospital Vall d’Hebron – Parkinson’s Disease
  2. Hospital Clinic – Multiple Sclerosis
  3. Hospital San Joan de Deu – rare diseases in neuropediatrics (example: Rett Syndrome)
  4. Hospital Bellvitge – Obsessive Compulsive Disorder and Major Depression Disorder
  5. Hospital Benito Menni – Schizophrenia
  6. CRG ­‐ Center for Genomic Regulation – Preclinical research in mice and humans with Down syndrome

We  have  developed  several  new  proprietary  algorithms.  The  first  patented  algorithm  is  for  the  multi-­modal visualization and interaction with the 3D complex maps of brain connections. By using a 3D motion infrared controller  (such  as  the  Leap  Motion)  we  have  patented  gestures  and  visualizations  for  exploration  and interaction  of  complex  brain  data  that  captures  different  brain  properties  encoded  by  tissue  contrast captured with the different MRI sequences employed in the acquisition.

The second patent is for the enhancement of poor quality/resolution images (provided by typical 1.5 Tesla MRI scanners in hospitals worldwide). When a scan is performed by a scanner with a lower magnetic field (as most scanners worldwide are), one known problem is the image quality or the noise present in the images. Our patent performs not only de-­noising but also enhancement of the data for better clinical use.

Investment & Exit

 

Current Round

Mint Labs is raising 500,000€:

  • 250K in the US
  • 100K through investors in Europe
  • 150K through Capital Cell
We're offering 4.54% of the company for 150K.

The estimated value of the company is at €3.3M, already backed by investment offers in California, Boston, and New York. Value gain is estimated as follows:

Financing Mint Labs - from 2014 to 2018

2014 - Mint Labs raised €240,000 with the initial financing pre­‐seed round being backed with €160,000 of long-term debt, which came from soft loans provided by the Spanish Government (ENISA and Institut Catala de Finances – ICF) to fund technology-­based companies. These loans are offered with 3­‐5 years of grace period  and  below  average  interest  rates. Wayra academy (a Telefonica innitiave) invested €80,000 in form of a convertible note.

2015 - A seed round of €500,000 after reaching the first sales to consolidate platform growth in EU (especially Spain, UK and Germany) and US markets. The company is in negotiations with business angels to raise the initially required €500,000. 150K is being raised for this round via Capital Cell

2017 - Series A round of €3,000,000 to consolidate growth in clinical trial areas and worldwide scaling. The expected track record and volume of sales will ensure the attractiveness for Venture Capital firms to invest. We already have been raising our network of VCs, and are updating them on our progress.

 

Exit Strategy

Mint Labs' exit strategy is via the acquisition by a cloud based medical imaging storage company (Lexmark, Teracon, Toshiba Medical), an MRI vendor (Philips, Siemens, GE) or an information company (Google, IBM). 

IBM for instance, is moving aggressively to expand the utility of its Watson artificial intelligence platform. It is planning to acquire Merge Healthcare, a RIS/PACS and advanced visualization developer, for a total of $1 billion in cash.

Some notable references in the field:

  • dnanexus (Mountain View, CA, US)
    • Genomic analysis cloud platform
    • Founded 2009
    • $1.6M Series A (2009)
    • $15M Series B (2011) Google Ventures, etc.
    • $15M Series C (2014) Google Ventures, etc.
  • Accelarad (Atlanta, GA, US)
    • Cloud technology for radiology sharing, hosts the exchange of 400 million medical images annually
    • Founded 2009
    • Acquired (2014) by Nuance Communications (hosting EHR, voice to speech reports, etc.)
    • $6 million a year in sales
  • Inovalon (Maryland, USA)
    • Cloud-based analytics platform for healthcare customers
    • Founded 1998
    • Reported $336 million in sales in 2014
    • First digital health IPO of 2015, raising $600 million
  • Health Catalyst (Salt Lake City, US)
    • Health Data warehouse and analytics platform
    • Series D of $70 million, with a $500 million valuation
    • Is planning an IPO in 2 years
  • Predilytics (Manchester, NH, US)
    • Advanced healthcare predictive analytic products, using big data
    • Founded 2011
    • $6M Series A (2012) Google Ventures
    • $4.5M Series B (2013)
    • $10M Series C (2014) Qualcomm Ventures

Drivers

The founders of Mint Labs bring together the experience and knowledge in the several areas covered: medical image processing, medical visualization, mobile solutions, and software engineering. They have been working together in the area of brain imaging for more than 9 years, with joint publication record.

PAULO RODRIGUES , PH .D.

Age: 34

Years of work Experience: 10

Short CV: Paulo was born in 1981 in Vila Franca, Portugal. After 5 year Licenciate studies, with merits, in computer science and systems engineering at the University of Minho in Braga, Portugal, he worked in an innovative IT mobility company. In 2006, he started his PhD research in the BMIA group of the department of Biomedical Engineering at Eindhoven University of Technology. His research focused on developing novel tools for the virtual dissection of the human brain white matter structures. After the PhD work, he held a software engineering position, for 1 year, in a successful Dutch IT company, leader in advanced planning and scheduling solutions, based on an inspiring general solution. He was a research associate position at the Department of Personality, Faculty of Psychology, Universitat Barcelona, Spain, where he exploited neuroimaging techniques to understand the neurobiological mechanisms in cognitive functions and disorders. He enrolled and was a finalist at the BioEmprenedorXXI program, in order to obtain more knowledge on business management and entrepreneurship. He led the successful application to the Wayra Academy program (accelerator of Telefonica). At the moment he is the CEO and co-founder of Mint Labs and has been awarded the MIT Technology Review Innovative Entrepreneur under 35.

VESNA  PRCHKOVSKA , PH .D.

Age: 32

Years of work Experience: 9

Short CV: Vesna was born in 1982 in Bitola, Macedonia. She studied 5 year engineering studies in computer science, informatics and control systems at the Faculty of Electrical Engineering at University Ss. Cyril and Methodius in Skopje. In 2006 she graduated with honors. From July 2006 she started her PhD research in the Biomedical Image Analysis (BMIA) group of the department of Biomedical Engineering at Eindhoven University of Technology. Her research focus was processing and visualization of high angular resolution diffusion imaging (HARDI) data. She published various papers for improvements in the acquisition, processing and visualization pipeline in diffusion tensor imaging (DTI) and HARDI. From December 2011 till February 2012, she was a visiting researcher at University Sans Malaysia, Penang, Malaysia, where she established important collaborations between Penang (Malaysia), Eindhoven (The Netherlands) and Barcelona (Spain). She recently finished her Marie Curie fellowship, where she was holding a research associate position at the Neuroimmunology group, part of IDIBAPS – Hospital Clinic research center, in Barcelona Spain. During her fellowship she was exploring neuroimaging techniques for the study of neurological disorders such as multiple sclerosis. She has experience in European public funding programs, and she has successfully mentored and supervised several students and MSc projects. She was a visiting researcher at Harvard Medical School in 2014, and she is still keeping the collaboration. She is a co-founder and CSO of Mint Labs.

 

LANDON MCKENNA

Age: 31

Years of work experience: 15

Short  CV:  Landon  was  born  in  1983  in  Boston  Massachusetts.  He  studied  business  management  at  Suffolk University.  He  founded  and  managed  two  private  companies  (one  international  import/export  company) with successful exits. He worked for Cypress Financial Group for 3 years in financial services. He specialized in  finance  (mutual  funds,  stocks,  bonds),  holding  a  series  6  securities  license  as  well  as  a  2-­‐15  insurance license.

 

Awards

 

Partners & Associates

Product/Service

Our flagship product, CloudN delivers a cloud based, 3D imaging data analysis and quantification without the need for any investment in data processing, storage hardware, or software.

CloudN addresses the critical issue of better utilizing multi-­‐modality imaging (MRI, CT, etc.) without the need for any additional capital expense. The platform is able to receive medical images acquired in preclinical and clinical   trials   from   Pharma   and/or   specialists,   hospitals   and   imaging   centres.   These   images   are   then processed  by  the  state-­‐of-­‐the-­‐art  algorithms  developed  in  Mint  Labs  that  are  automatically  employed  in order to identify patterns and anomalies related to clinical outcomes.

Currently, there are no tools able to emulate the capabilities of analysis and prediction as that of our product. This allows us to position ourselves as the new technology standard for monitoring and diagnosis of neurological disorders.

The analysis and diagnosis of neurological diseases will be directed at neurodegenerative diseases: Alzheimer's, Parkinson's and Multiple Sclerosis, as they are extremely complicated to diagnose at an early stage and can benefit the most from our imaging quantification tools. First, we approach specialists and organizations working on the study and development of new treatments for these disorders (with a need for quantification tools to evaluate brain changes and differences among patients e.g., placebo versus medicine). They are our first clients and the first stakeholders in the R&D pipeline (see section 3.1). As a second stage, we will approach the clinical trials stakeholders (pharma, CROs) to support clinical trial stages evaluating the efficacy of new treatments in patients.

In the next development phase, the platform will provide knowledge-­‐based diagnostic information based on “Big Data” analysis of acquired images and related clinical information. This will be performed by monitoring over  time  different  data  as  brain  imaging  analysis,  sleep  patterns  or  cognitive  abilities.  The  analysis  of  the interrelationships between these factors is expected to allow diagnosis of neurodegenerative diseases years in advance compared to current techniques and technologies.

We have 2 provisional patents to protect our different algorithms developed within the company (filed January 2015) and we expect to file them in Q3 of 2015.

Market

  • Considering the number of open studies in http://clinicaltrials.gov
  • If using imaging markers can lead to €45M cost reduction, meaning a €15k saved per subject
  • Assuming an initial average price per brain image processing of €5 000
  • We are targeting a global market of more than €13B.

Foreseeable addressable clinical trial market of €13B, with focus on specific neurological diseases, and clinical trials phases 2, 3. We will focus initially on AD, PD and MS as a market of €4B.

Competitors

We  are  the  first  multi­‐modal  imaging  cloud  platform,  focused  on  the  brain.  We  provide  medical  data management (data privacy compliant) and advanced (proprietary) quantification.

Competitors are simple cloud storage (MIM cloud, Calgary Scientific) without our advanced image quantification capabilities; or imaging expert tools targeted at imaging experts (Olea or FEI).

We can divide Mint Labs competitors in three groups:

Imaging informatics platform

  • New market, research focused, open-­‐source solutions
  • XNAT, COINS

Cloud storage

  • New market, difficult channel, integrated with EMR or via mobile
  • MIM cloud, Calgary Scientific, Toshiba (Vital Images), Afga, Carestream, TeraMedica

Advanced Neuroimaging

  • Niche market, tools developed by imaging experts for imaging experts
  • Olea, FEI, BrainInnovation

 

Marketing & sales

Mint Labs will work closely with R&D organizations of international prestige to validate the analytics and predictive power of the platform. Once the technology is validated the company expects to use its own sales and reputation gained through the collaborations with leading research groups in order to attract the first customers between the clinical trials stakeholders (pharmaceutical companies, CROs, patient recruitment companies).

From the beginning the focus of the company is international, although there will be a special emphasis on the European and North American markets, as this is where the company has a larger network.

PHASE 1: PRE-CLINICAL STAGE

Mint Labs current focus (during 2015) is to grow the following in the pre-clinical stage market by specific marketing strategy, as presence in scientific and medical symposiums (ISMRM, RSNA, MICCAI, etc.). We will also conduct several research projects (in collaboration with top scientific institutes) with great PR potential: for   instance   the   ‘brain   of   success’   pinpointing   the   brain   areas   related   to   personality   features   in entrepreneurs  minds/brains,  together  with  Hospital  Clinic  (Barcelona),  Wayra  Academy  (Telefonica  startup accelerator) and the Center for Advanced Brain Imaging (CABI), Atlanta, GA, US.

Approach: The main sales tool in this phase is the ‘trial credits’. We reach specialists through online offers of trial credits (e.g. free 10 GB of storage and 20 processing credits) through professional channels (linkedin, twitter, academia, research gate, etc.), and through own sales force with presence in scientific and medical conferences. Specialists are also instrumental to expand to the respective organizations (and increase use base).

Objective: By growing our user base, and having more data in the platform, we also derive the metrics necessary to adjust the value proposition for phase 2 -­‐  the amount of time and costs reduced by the 

accurate quantification/monitoring of patients; the amount of cost reduction is provided by using our cloud platform brain quantification.

CHANNELS :

  • Trial periods is the ‘key’ channel for this phase
  • Direct sales at science and medical conferences (e.g. ISMRM, RSNA)
  • Online marketing offering trial periods (e.g. linkedin, researchgate, academia)
  • Active scientific presence and collaborations with key opinion leaders (e.g. Martinos Center  in Boston, Fundacion Pasqual Maragall and Hospital Vall d’Hebron in Barcelona, …)
  • We especially focus in approaching specialists and organizations involved in Alzheimer’s disease, Parkinson’s Disease and Multiple Sclerosis.

CUSTOMER  RELATIONSHIP:

  • Attract with trial periods (offering free storage, free processing credits)
  • Convert  by  cost  optimization,  through  added  value  (quantification  tools)  and  easy-­‐to-­‐use  cloud platform
  • Retain  with  unique  features  available  only  through  platform  (e.g.  touch-­‐less  visualization,  seamless collaboration through sharing data and tools)
  • Attract and retain through scientific consultancy support -­‐ we are a research partner.

PHASE 2: CLINICAL TRIAL STAGE

Leveraging on the network of prescribers and influencers (specialists and organizations conducting studies and analysis of patients with neurological diseases) we will attract the first clinical trial customers. We expect to have the first pilots with pharma companies by the Q3 of 2015.

Other key aspect will be working with patient organizations, as the EPDA (European Association  of Parkinson) since they are usually a source for recruitment of patients for medical tests and could exercise prescribers between different actors in the clinical trials sector.

Finally, Mint Labs will attend major conferences in neurological diseases, (e.g. AD/PD congress, International Stroke Conference, etc.) to deepen their knowledge of the industry and network with other actors involved.

CHANNELS :

  • Mint Labs sales team will leverage on the validated technology (with phase 1) to attract pharmaceutical companies, CROs and clinical trial recruitment companies
  • Direct sales at science, medical and trade conferences (e.g. ISMRM, AD/PD conference, International Stroke conference, etc.).

CUSTOMER RELATIONSHIPS:

  • Mint Labs sales team will leverage on the validated technology and reputation gained through collaboration with leading research groups to attract first customers between pharmaceutical companies, CROs and clinical trial recruitment companies
  • We will cultivate a strong relationship with researchers to contribute in the understanding of the disease and create a network of prescribers that can recommend our products to clinical trials stakeholders.

Roadmap

Mint Labs approach to market passes by 2 phases: first focusing on supporting R&D of studies and analysis working on understanding the brain and neurological diseases; second supporting clinical trials evaluating new treatments for neurological diseases. First phase provides the validation and the referrals necessary to enter the clinical trial market.

The following scheme illustrates the go-­‐to-­‐market stages, distinguishing the different segments (parallel to the clinical trial phases) we will be addressing.

PHASE 1: PRE-­CLINICAL STAGE

We  will  start  by  focusing  on  the  pre-­clinical  market.  This  comprises  of  specialists  that  are  developing  new therapies for neurological diseases (neurologists, neurosurgeons, psychiatrists, neuroscientists).

They have access to the patients and gather medical images and data to explore and validate their hypothesis on the function (and malfunction) of the brain. By approaching the individual specialists, we build the recognition and validation of our platform and products.

Having the specialists and research groups committed, we can move to establish a recurrent deal with the R&D organizations conducting studies and analysis of patients with neurological diseases. Biotech companies are also potential clients (e.g. iproteos.com researching new protein compound  for schizophrenia) as they require quantification tools to evaluate the performance of their treatment, typically in animal models (mice, rats).

Value Proposition:

Non-subjective in vivo quantification of brain structure and circuits

Reduced computational and storage costs -­ no need to invest in creating and upgrading a large group of computers (local cluster), and no need to install and maintain software since everything is accessible within the browser

Reduced time and costs in R&D of new therapies, with faster results from the analysis, due to optimized processing pipelines in the cloud

Accelerated development of biomarkers for neurological diseases, with reproducible pipelines and publishing/sharing of results within the team and consortiums.

Market Size:

  • Considering 5.28 million MRI head scans yearly in EU, and 6.6 million in US
  • Adjusting to the prevalence of each brain disease (as in Table 1 and 2)
  • Assuming an average price tag of € 200 ($ 215) per image processed by us

PHASE 2: CLINICAL TRIAL STAGE

Having the specialists and R&D organizations committed, we can move to establish initial clients within the clinical trial segment. Here we consider clinical trial stakeholders such as: Pharmaceutical companies (e.g. Novartis, Merck, Pfizer), contract research organization (CROs) and clinical trials recruitment companies.

The main factors of purchase will be, first, to have a greater level of detail on brain changes and all parameters monitored during a clinical trial. This would shorten the clinical testing of new treatments, thus reducing development costs and time to market. Furthermore, the cost is reduced with patient recruitment, since the average cost of each patient recruited for clinical trials is € 60,000 ($ 64,400), while the company expected to charge a fee of € 15,000 ($ 16,100).

The greatest expected value of our platform will be for phases 2 and 3 of clinical trials, since their goal is to evaluate the efficacy in groups of patients receiving the treatment or a placebo. Our quantification provides an objective way to evaluate this efficacy.

As a reference case, lets consider Alzheimer’s disease clinical trial design:

  • Phase 3 trials last in average 18 months and study 337 patients per group
  • Each   patient   is   imaged   7   times   with   MRI,   screening   and   longitudinal   (besides   other   imaging modalities like PET, and other multi-­‐modal data like clinical scores, etc.)
  • The use of imaging biomarkers can drastically reduce costs by better selecting patients as well as monitoring progress. The conservative estimate is €45M ($48.3M) cost reduction in a trial thanks to imaging – that is €113k ($121.3k) average cost reduction per patient in the study.

Value proposition:

  • Reducing R&D costs in new treatments through identifying more adequate patients for clinical trials (providing better tools to profile patients for clinical trials)
  • Reducing R&D costs by better assessment of a treatment’s effects (by measuring changes in brain)
  • Furthermore, through home remote monitoring (integrating medical devices and other sources of data at patient’s home), patient’s adherence and retention to the trial are likely to increase

 

Forecast

Mint Labs platform will be increasingly used, firstly in pre-­clinical stage (specialists and R&D organizations) providing a stable growing  revenue. As validation and referrals occur, we will approach clinical trial stage, first conducting a pilot (Q3 of 2015), and then supporting first trials.

If you would like to know more details about our financial projections, do not hesitate to contact us.

    2014 2015       2016 2017
METRICS     Q1 Q2 Q3 Q4    
Headcount Summary              
  Sales     1 1 3 3 6 14
  Marketing         1 1 4 11
  R&D   2 3 4 7 7 13 16
  G&A   2 2 2 3 3 6 7
Total   4 6 7 14 14 29 48
                 
Data Summary              
  New Brain Image sets   209 1921 1716 2947 5807 7002
  Paid Brain Image sets   23 168 925 2947 2320 8737
Total   799 1031 3120 5762 11656 19783 35523

Investment details

Exit details

Mint Labs is raising 500.000€:

  • 250K in the US
  • 100K through investors in Europe
  • 150K through Capital Cell
We're offering 4,54% of the company for 150K.

The estimated value of the company is at 3M, already backed by investment offers in California. Value gain is estimated as follows:

 

Exit Strategy

Mint Labs' return strategy is via acquisition by cloud based medical imaging storage (Lexmark, Teracon, Toshiba Medical, MRI vendor (Phillips, Siemens, GE) or information company (Google).

As a reference, here are some similar exits in 2014 and 2015:

  • dnanexus (Mountain View, CA, US)
    • Genomic analysis cloud platform
    • Founded 2009
    • $1.6M Series A (2009)
    • $15M Series B (2011) Google Ventures, etc.
    • $15M Series C (2014) Google Ventures, etc.
  • Accelarad (Atlanta, GA, US)
    • Cloud technology for radiology sharing, hosts the exchange of 400 million medical images annually
    • Founded 2009
    • Acquired (2014) by Nuance Communications (hosting EHR, voice to speech reports, etc.)
    • $6 million a year in sales (?)
  • Predilytics (Manchester, NH, US)
    • Advanced healthcare predictive analytic products, using big data
    • Founded 2011
    • $6M Series A (2012) Google Ventures
    • $4.5M Series B (2013)
    • $10M Series C (2014) Qualcomm Ventures